• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因特征可预测根治性治疗后原发性前列腺癌患者的生化无复发生存。

Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.

机构信息

Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

出版信息

Cancer Med. 2021 Sep;10(18):6492-6502. doi: 10.1002/cam4.4092. Epub 2021 Aug 28.

DOI:10.1002/cam4.4092
PMID:34453418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8446568/
Abstract

BACKGROUND

This study evaluated the predictive value of gene signatures for biochemical recurrence (BCR) in primary prostate cancer (PCa) patients.

METHODS

Clinical features and gene expression profiles of PCa patients were attained from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets, which were further classified into a training set (n = 419), a validation set (n = 403). The least absolute shrinkage and selection operator Cox (LASSO-Cox) method was used to select discriminative gene signatures in training set for biochemical recurrence-free survival (BCRFS). Selected gene signatures established a risk score system. Univariate and multivariate analyses of prognostic factors about BCRFS were performed using the Cox proportional hazards regression models. A nomogram based on multivariate analysis was plotted to facilitate clinical application. Kyoto Encyclopedia of Gene and Genomes (KEGG) and Gene Ontology (GO) analyses were then executed for differentially expressed genes (DEGs).

RESULTS

Notably, the risk score could significantly identify BCRFS by time-dependent receiver operating characteristic (t-ROC) curves in the training set (3-year area under the curve (AUC) = 0.820, 5-year AUC = 0.809) and the validation set (3-year AUC = 0.723, 5-year AUC = 0.733).

CONCLUSIONS

Clinically, the nomogram model, which incorporates Gleason score and the risk score, could effectively predict BCRFS and potentially be utilized as a useful tool for the screening of BCRFS in PCa.

摘要

背景

本研究评估了基因特征对原发性前列腺癌(PCa)患者生化复发(BCR)的预测价值。

方法

从基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)数据库中获得 PCa 患者的临床特征和基因表达谱,并将其进一步分为训练集(n=419)和验证集(n=403)。最小绝对收缩和选择算子 Cox(LASSO-Cox)方法用于在训练集中选择用于生化无复发生存(BCRFS)的鉴别基因特征。选择的基因特征建立了风险评分系统。使用 Cox 比例风险回归模型对 BCRFS 的预后因素进行单因素和多因素分析。基于多因素分析绘制列线图以促进临床应用。然后对差异表达基因(DEGs)进行京都基因与基因组百科全书(KEGG)和基因本体论(GO)分析。

结果

值得注意的是,风险评分可以通过时间依赖性接收器工作特征(t-ROC)曲线在训练集(3 年 AUC=0.820,5 年 AUC=0.809)和验证集(3 年 AUC=0.723,5 年 AUC=0.733)中显著识别 BCRFS。

结论

临床上,包含 Gleason 评分和风险评分的列线图模型可以有效预测 BCRFS,并且可能被用作 PCa 中 BCRFS 筛查的有用工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/d5cefc88da4c/CAM4-10-6492-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/e31fe0ae7819/CAM4-10-6492-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/e120e2c9fc0d/CAM4-10-6492-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/29ea5008c2e2/CAM4-10-6492-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/cd1a6412189b/CAM4-10-6492-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/ccf2f2513c8e/CAM4-10-6492-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/d5cefc88da4c/CAM4-10-6492-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/e31fe0ae7819/CAM4-10-6492-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/e120e2c9fc0d/CAM4-10-6492-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/29ea5008c2e2/CAM4-10-6492-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/cd1a6412189b/CAM4-10-6492-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/ccf2f2513c8e/CAM4-10-6492-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c26/8446568/d5cefc88da4c/CAM4-10-6492-g004.jpg

相似文献

1
Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.基因特征可预测根治性治疗后原发性前列腺癌患者的生化无复发生存。
Cancer Med. 2021 Sep;10(18):6492-6502. doi: 10.1002/cam4.4092. Epub 2021 Aug 28.
2
Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.使用三代谢基因风险评分模型预测前列腺癌患者的生化无复发生存。
BMC Cancer. 2022 Mar 4;22(1):239. doi: 10.1186/s12885-022-09331-8.
3
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.基于统计分析构建新型膀胱癌 mRNA 特征预测预后模型。
BMC Cancer. 2021 Jul 27;21(1):858. doi: 10.1186/s12885-021-08611-z.
4
Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.构建并验证基于癌症干细胞相关基因集的稳健签名,以预测前列腺癌早期生化复发。
Dis Markers. 2020 Oct 9;2020:8860788. doi: 10.1155/2020/8860788. eCollection 2020.
5
Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.基于 15 个 miRNA 的特征signature 是预测前列腺癌患者预后的可靠工具。
Int J Med Sci. 2021 Jan 1;18(1):284-294. doi: 10.7150/ijms.49412. eCollection 2021.
6
Metabolic-related gene signature model forecasts biochemical relapse in primary prostate cancer.代谢相关基因特征模型预测原发性前列腺癌的生化复发。
Annu Int Conf IEEE Eng Med Biol Soc. 2022 Jul;2022:65-68. doi: 10.1109/EMBC48229.2022.9871189.
7
A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.一个新的 13 个 RNA 结合蛋白(RBPs)标志物可以预测前列腺癌的生化复发。
Pathol Res Pract. 2021 Sep;225:153587. doi: 10.1016/j.prp.2021.153587. Epub 2021 Aug 13.
8
DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.DNA 甲基化分析预测Ⅰ期肺腺癌复发风险:用于临床管理的列线图的建立和验证。
J Cell Mol Med. 2020 Jul;24(13):7576-7589. doi: 10.1111/jcmm.15393. Epub 2020 Jun 12.
9
A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.一种潜在的由四种长链非编码RNA组成的标志物可预测前列腺癌的无生化复发生存率和无病生存率。
Int Urol Nephrol. 2017 May;49(5):825-835. doi: 10.1007/s11255-017-1536-8. Epub 2017 Feb 10.
10
Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.鉴定铁死亡相关基因特征在乳腺癌患者中的预后价值。
BMC Cancer. 2021 May 31;21(1):645. doi: 10.1186/s12885-021-08341-2.

引用本文的文献

1
A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.一种新型的肿瘤纯度和免疫浸润相关模型,用于预测前列腺癌的无远处转移生存。
Eur J Med Res. 2023 Nov 28;28(1):545. doi: 10.1186/s40001-023-01522-8.
2
Construction of miRNA-mRNA network and a nomogram model of prognostic analysis for prostate cancer.前列腺癌miRNA-mRNA网络构建及预后分析列线图模型
Transl Cancer Res. 2022 Aug;11(8):2562-2571. doi: 10.21037/tcr-22-653.
3
Discovering Gene Signature Shared by Prostate Cancer and Neurodegenerative Diseases Based on the Bioinformatics Approach.

本文引用的文献

1
Radiologist-like artificial intelligence for grade group prediction of radical prostatectomy for reducing upgrading and downgrading from biopsy.用于预测根治性前列腺切除术分级组的类放射科医生人工智能,以减少活检的升级和降级。
Theranostics. 2020 Sep 2;10(22):10200-10212. doi: 10.7150/thno.48706. eCollection 2020.
2
Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.机器人辅助根治性前列腺切除术加扩大淋巴结清扫术后小体积淋巴结受累和生化复发的前列腺癌。
Int J Clin Oncol. 2020 Jul;25(7):1398-1404. doi: 10.1007/s10147-020-01682-1. Epub 2020 Apr 24.
3
基于生物信息学方法发现前列腺癌和神经退行性疾病的基因特征共享
Comput Math Methods Med. 2022 Jun 28;2022:8430485. doi: 10.1155/2022/8430485. eCollection 2022.
4
A Novel Angiogenesis-Related Gene Signature to Predict Biochemical Recurrence of Patients with Prostate Cancer following Radical Therapy.一种用于预测前列腺癌患者根治性治疗后生化复发的新型血管生成相关基因特征。
J Oncol. 2022 Jun 28;2022:2448428. doi: 10.1155/2022/2448428. eCollection 2022.
Cancer statistics, 2020.
癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy.一种基于新型基因特征的模型可预测前列腺癌患者根治性前列腺切除术后的无生化复发生存率。
Cancers (Basel). 2019 Dec 18;12(1):1. doi: 10.3390/cancers12010001.
5
Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.通过整合 DNA 甲基化和 mRNA 表达谱分析鉴定侵袭性临床无功能垂体腺瘤的关键基因。
J Transl Med. 2019 Dec 3;17(1):407. doi: 10.1186/s12967-019-02148-3.
6
Assessment of biochemical recurrence of prostate cancer (Review).前列腺癌生化复发的评估(综述)。
Int J Oncol. 2019 Dec;55(6):1194-1212. doi: 10.3892/ijo.2019.4893. Epub 2019 Oct 4.
7
Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases.高危前列腺癌病例中保留神经与不保留神经的机器人辅助根治性前列腺切除术的临床和肿瘤学结果
Oncol Lett. 2019 Oct;18(4):3896-3902. doi: 10.3892/ol.2019.10692. Epub 2019 Jul 31.
8
Effect of PTEN loss on metabolic reprogramming in prostate cancer cells.PTEN缺失对前列腺癌细胞代谢重编程的影响。
Oncol Lett. 2019 Mar;17(3):2856-2866. doi: 10.3892/ol.2019.9932. Epub 2019 Jan 14.
9
CRTC2 as a novel prognostic biomarker for worse pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with prostate cancer.CRTC2 作为一种新型预后生物标志物,与前列腺癌患者根治性前列腺切除术后较差的病理结局和生化复发相关。
Investig Clin Urol. 2019 Mar;60(2):84-90. doi: 10.4111/icu.2019.60.2.84. Epub 2019 Feb 19.
10
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.